Posted by Michael Wonder on 12 Dec 2019
European Commission approves Evenity (romosozumab) for the treatment of severe osteoporosis in post-menopausal women at high risk of fracture
11 December 2019 - First New Osteoporosis Medicine Approved in the European Union Since 2010.
Amgen and UCB today announced that the European Commission has granted marketing authorization for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. Evenity is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).
The approval follows a positive opinion from the Committee for Medicinal Products for Human Use that was received in October 2019. The first launches of Evenity in the European Economic Area are planned for first half of 2020.
